Market Place
Sourcing Support
Pentixapharm Acquires Target Discovery Business of Glycotope
03 Jul 2024 //
GLOBENEWSWIRE
Glycotope to Present Platform Approach for Development at 2024 AACR Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Glycotope and Evotec enter licensing agreement
11 Dec 2023 //
GLOBENEWSWIRE
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 SITC Meeting
03 Nov 2023 //
GLOBENEWSWIRE
LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope
16 Oct 2023 //
GLOBENEWSWIRE
Glycotope and Max Delbr¼ck Center enter into research collaboration
25 Sep 2023 //
GLOBENEWSWIRE
Glycotope Presents Glyco-Engineered Cell Lines at the 2023 (AACR) Meeting
17 Apr 2023 //
GLOBENEWSWIRE
Therabest & Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100
13 Dec 2022 //
GLOBENEWSWIRE
Glycotope Presents GlycoTarget Platform & New Data Platform-Derived anti-LYPD3
07 Nov 2022 //
GLOBENEWSWIRE
LegoChem, Glycotope Collaborate and License Agreement for Ab for use as ADC
11 Jul 2022 //
GLOBENEWSWIRE
Glycotope Presents New Data on Antibodies and Fusion-Proteins at AACR
07 Apr 2022 //
GLOBENEWSWIRE
Glycotope Announces New Strategy for Uniquely-Tumor Specific Antibody Platform
24 Mar 2022 //
GLOBENEWSWIRE
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH
01 Feb 2022 //
GLOBENEWSWIRE
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies
15 Nov 2021 //
GLOBENEWSWIRE
Glycotope Announces Poster Presentations at the 2021 (ASCO)
30 Apr 2021 //
GLOBENEWSWIRE
Octapharma AG Invests €80 Million to Acquire an Exclusive Worldwide License
09 Oct 2015 //
THE FINANCIAL EXPRESS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.